Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Edesa Biotech, Inc.

Market Cap 52.78M 45.49M 41.87M 39.28M 73.78M 4.99B 74.52M 495M 193M 2.44B 198M 194M 8.45B P/E Ratio 2026 *
-3.78x
P/E Ratio 2027 * -3.03x
Enterprise Value 52.78M 45.49M 41.87M 39.28M 73.78M 4.99B 74.52M 495M 193M 2.44B 198M 194M 8.45B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
81.13%
Yield 2026 *
-
Yield 2027 * -
1 day-3.79%
1 week+17.41%
Current month-19.67%
1 month-35.56%
3 months+13.28%
6 months+290.57%
Current year+308.45%
1 week 4.79
Extreme 4.79
6.27
1 month 4.56
Extreme 4.56
13.3
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
84
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 31/07/2015
Director of Finance/CFO 57 30/04/2025
President 48 06/06/2019
Director TitleAgeSince
Chairman 50 06/06/2019
Director/Board Member 55 06/06/2019
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap.
05-31Free

Founder

1,671 0.0188%
05-26Free

Chief Financial Officer

64,609 0.7271%
05-26Free

Chairperson

64,609 0.7271%
Change 5-day change 1-year change 3-year change Capi.($)
-2.36%+17.41%+181.55%-1.36% 52.78M
-0.47%-0.24%+56.53%+107.29% 54.92B
-0.34%+3.51%+45.55%+40.16% 44.31B
-0.44%+4.62%-14.89%-19.59% 22.96B
-2.15%-3.75%-6.16%+376.65% 21.12B
-2.91%+0.27%+13.28%-36.73% 16.31B
-2.15%-3.20%+5.73%-41.76% 15.19B
-0.12%+0.22%+27.20%+178.18% 13.32B
+1.48%+9.81%+19.29% - 12.48B
+0.32%+2.81%+96.37%+213.49% 11.21B
Average -1.11%+3.54%+42.45%+90.70% 21.19B
Weighted average by Cap. -0.82%+2.86%+31.38%+93.84%

Financials

2026 *2027 *
Net sales - -
Net income -13.5M -11.64M -10.71M -10.05M -18.87M -1.28B -19.06M -127M -49.45M -625M -50.66M -49.59M -2.16B -26.75M -23.06M -21.22M -19.91M -37.39M -2.53B -37.77M -251M -97.99M -1.24B -100M -98.26M -4.28B
Net Debt - -
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
17
Date Price Change Volume
16/06/26 5.800 $ -2.36% 13,811
15/06/26 5.940 $ +2.41% 185,978
12/06/26 5.800 $ +2.65% 180,117
11/06/26 5.650 $ +8.45% 508,937
10/06/26 5.210 $ +5.47% 149,934
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.940USD
Average target price
14.00USD
Spread / Average Target
+135.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EDSA Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!